SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001104659-22-002505
Filing Date
2022-01-10
Accepted
2022-01-10 08:00:20
Documents
12
Period of Report
2021-12-20
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A tm222250d1_8ka.htm   iXBRL 8-K/A 33374
  Complete submission text file 0001104659-22-002505.txt   210633

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA scps-20211220.xsd EX-101.SCH 3210
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE scps-20211220_lab.xml EX-101.LAB 34594
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE scps-20211220_pre.xml EX-101.PRE 22727
6 EXTRACTED XBRL INSTANCE DOCUMENT tm222250d1_8ka_htm.xml XML 3711
Mailing Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170 (212) 479-2513
Scopus BioPharma Inc. (Filer) CIK: 0001772028 (see all company filings)

IRS No.: 821248020 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39788 | Film No.: 22519738
SIC: 2834 Pharmaceutical Preparations